Stefano Galli
Latest contributions
Novel Hertz Contact Intravascular Lithotripsy: could we achieve more in calcium modification?
22 May 2025 – From EuroPCR 2025
Discover how the novel Hertz Contact Intravascular Lithotripsy (IVL) is pushing the boundaries of calcium modification in challenging coronary lesions.
This EuroPCR 2025 session shares real-world insights confirming the promising results of the PINNACLE I trial, with LithiX IVL proving safe and effective across eccentric, concentric, and...
Cracking the calcium code - Novelty and utility of Hertz Contact intravascular lithotripsy
15 May 2024 – From EuroPCR 2024
Follow this session to learn about the novel HC-IVL system, its application for moderate to severe calcified lesions, and procedural tips. The LithiX Hertz Contact IVL addresses unmet needs in coronary artery calcification by offering a simplified workflow with fewer devices and effective treatment for difficult...
Artificial intelligence-powered quantification of coronary physiology and vulnerable plaque: opportunities for novel treatment options
15 May 2024 – From EuroPCR 2024
In this session, uncover new data on Murray-law based quantitative flow ratio (muFR) assessment, providing a comprehensive understanding of PCI outcomes from a single angiographic view, explore the innovative application of artificial intelligence in identifying vulnerable plaque and assessing hemodynamic stenosis significance through the analysis of...
Calcified coronary lesions: procedural techniques - Part 1
14 May 2024 – From EuroPCR 2024
This session will feature a series of selected clinical case submissions from EuroPCR 2024, focusing on procedural techniques for the management of calcified coronary lesions. Attendees will have the opportunity to explore various strategies, including the use of angio-based FFR, OCT, rotational atherectomy, and drug-coated balloons,...
Hotline: new coronary devices (DES, BRS, DCB)
14 May 2024 – From EuroPCR 2024
This hotline session provides a comprehensive overview of the latest clinical data on new coronary devices, including bioresorbable scaffolds, drug-coated balloons, and drug-eluting stents. Participants will learn about the outcomes of various randomized trials and registry studies, examining the performance of these innovative technologies in different...
Evolution of complex PCI: cross, modify it, and be precise!
14 May 2024 – From EuroPCR 2024
Don't miss this session for expert guidance on preparing and managing complex lesions. Gain insights into choosing the right tools, including microcatheters and balloons, for optimal treatment outcomes. Explore the innovative features of flagship devices for complex PCI, and Pronavi microcatheter and Alveo HP CTO balloon...
Where deliverability matters: challenging cases requiring a low profile
18 May 2021 – From EuroPCR 2021
Watch this session presented by Robert Byrne, Ralph Toelg, Stefano Galli, Farrel Hellig and Jack Tan in order to participate in interactive reviews of interesting DES, DCB and covered stent cases and outcomes, to assess where ultrathin DES, DCB and covered stent provide a clinical benefit, and to...
Exploring evidence and experience with magnesium scaffold Magmaris
23 May 2019 – From EuroPCR 2019
Consult this session on magnesium scaffold Magmaris to learn more about the available data on its clinical use and to review interesting intravascular imaging data after Magmaris implantation.
Coronary drug-coated balloons - Why, when and how
23 May 2019 – From EuroPCR 2019
Consult this session to discover practical tips about coronary drug-coated balloon, and learn more about its use, where it may provide a clinical benefit, and more!
Future and scope of sirolimus-coated balloon in peripheral vascular treatment
22 May 2019 – From EuroPCR 2019
Consult this session to learn more about the emerging sirolimus-coated balloon (SCB) technology in peripheral vascular treatment. Discover the SCB with NANOLUTE technology clinical outcome in below-the-knee (BTK) and superficial femoral artery (SFA) indications, and in arteriovenous fistula (AVF) and arteriovenous graft (AVG) indications.
